# Fluid shifts are main drivers for microgravity simulation-induced immune-physiological changes: findings from the VIVALDI studies

**Authors:** Dominique Moser, Marie-Pierre Bareille, Angelique van Ombergen, Marion Hoerl, Federico D´Amico, Matthias Feuerecker, Christopher Dächert, Sandra Matzel, Adrien Robin, Nastassia Navasiolava, Marc-Antoine Custaud, Alexander Choukér

PMC · DOI: 10.1038/s41526-025-00555-z · NPJ Microgravity · 2026-02-16

## TL;DR

This study shows that fluid shifts during microgravity simulations cause immune changes in both men and women, with effects stronger than other methods.

## Contribution

The study introduces a new perspective on how fluid shifts, not biological sex, primarily drive immune changes during microgravity simulations.

## Key findings

- Both sexes showed increased granulocytes and NK cells and decreased T-cells during dry immersion.
- Females had higher Torque-Teno-virus shedding after the simulation.
- Dry immersion caused stronger immune and fluid changes compared to head-down tilt bed rest.

## Abstract

Microgravity strongly affects human physiology during spaceflight. Biological sex has not yet been sufficiently considered as a variable for spaceflight deconditioning. The VivalDI studies investigated physiological systems affected by 5-days dry immersion (DI) in females and males, with a focus on immune changes in this report. In both sexes proportions of peripheral granulocytes and NK cells were elevated during DI and T-cell numbers were reduced. Leukocyte activation and cytokine levels were moderately affected. Females showed a higher Torque-Teno-virus shedding at the end of DI. Noradrenaline concentrations increased during the study with sex-specific patterns. Hemodynamics suggest that immunological changes were caused by DI-induced fluid shifts. Moreover, male study participants’ patterns were compared to a historical data set from a 5-days head-down-tilt bed rest (HDT-BR) study. Changes in leukocyte proportions and body fluid indicators were stronger in DI versus HDT-BR. These analyses indicate that fluid shifts primarily drive intervention-related immune-physiological differences, independent of biological sex. ClinicalTrials.gov, TRN: NCT05043974 and NCT05493176.

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, CD86 (CD86 molecule) [NCBI Gene 942] {aka B7-2, B7.2, B70, BU63, CD28LG2, CD86 v6}, CD28 (CD28 molecule) [NCBI Gene 940] {aka IMD123, Tp44}, FCGR3A (Fc gamma receptor IIIa) [NCBI Gene 2214] {aka CD16-II, CD16A, FCG3, FCGR3, FCRIIIA, FcGRIIIA}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, CEACAM8 (CEA cell adhesion molecule 8) [NCBI Gene 1088] {aka CD66b, CD67, CGM6, NCA-95}, CAT (catalase) [NCBI Gene 847], IL1RN (interleukin 1 receptor antagonist) [NCBI Gene 3557] {aka CRMO2, DIRA, ICIL-1RA, IL-1RN, IL-1ra, IL-1ra3}, CD14 (CD14 molecule) [NCBI Gene 929], CD40 (CD40 molecule) [NCBI Gene 958] {aka Bp50, CDW40, TNFRSF5, p50}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, ITGAM (integrin subunit alpha M) [NCBI Gene 3684] {aka CD11B, CR3A, HNA-4, MAC-1, MAC1A, MO1A}, CD4 (CD4 molecule) [NCBI Gene 920] {aka CD4mut, IMD79, Leu-3, OKT4D, T4}, CCL4 (C-C motif chemokine ligand 4) [NCBI Gene 6351] {aka ACT2, AT744.1, G-26, HC21, LAG-1, LAG1}, TTF2 (transcription termination factor 2) [NCBI Gene 8458] {aka HuF2, ZGRF6}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, CSF3 (colony stimulating factor 3) [NCBI Gene 1440] {aka C17orf33, CSF3OS, GCSF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, TLR4 (toll like receptor 4) [NCBI Gene 7099] {aka ARMD10, CD284, TLR-4, TOLL}, TLR2 (toll like receptor 2) [NCBI Gene 7097] {aka CD282, TIL4}, IL1B (interleukin 1 beta) [NCBI Gene 3553] {aka IL-1, IL1-BETA, IL1F2, IL1beta}, CD80 (CD80 molecule) [NCBI Gene 941] {aka B7, B7-1, B7.1, BB1, CD28LG, CD28LG1}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}
- **Diseases:** back pain (MESH:D001416), hypovolemia (MESH:D020896), immune dysfunctions (MESH:D007154), infection (MESH:D007239), immune dysregulation (OMIM:614878), Fluid (MESH:D002559), volume loss (MESH:D016388), inflammation (MESH:D007249), orthostatic intolerance (MESH:D054971), swelling (MESH:D004487), water loss (MESH:D000069578), DI (MESH:D007102), inflammatory and autoimmune diseases (MESH:D001327), jugular vein (MESH:D005925), hypotension (MESH:D007022)
- **Chemicals:** DI (-), catecholamine (MESH:D002395), DHEA (MESH:D003687), steroid (MESH:D013256), dopamine (MESH:D004298), PBS (MESH:D007854), Adrenaline (MESH:D004837), dehydroepiandrosterone sulfate (MESH:D019314), EDTA (MESH:D004492), Cortisol (MESH:D006854), water (MESH:D014867), Noradrenaline (MESH:D009638)
- **Species:** Homo sapiens (human, species) [taxon 9606], human gammaherpesvirus 4 (Epstein Barr virus, no rank) [taxon 10376], Torque teno virus (species) [taxon 68887]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12914047/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12914047/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12914047/full.md

---
Source: https://tomesphere.com/paper/PMC12914047